A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis.

ovartis Pharma Services AG0 个研究点目标入组 56 人开始时间: 2013年10月8日最近更新: 2016年4月11日

试验速览

暂无简介。

•Written informed consent must be obtained before any assessment is performed.
•Patients who have been defined as definite or probable” based on the criteria of Bohan and Peter (Bohan and Peter 1975) for dermatomyositis at least 3 months before screening
•Patients must have active disease as defined by muscle weakness
•Patients must have responded inadequately to previous standard of care or have demonstrated significant toxicity or intolerance to such therapies.
•Patients may be on a stable dose of corticosteroid (up/equal to 20 mg once daily prednisone equivalent)
•Patients currently treated with oral or subcutaneous MTX must have been a stable dose of no more/equal to than 25 mg per week
•Patients currently treated with Azathioprine must have been a stable maintenance dose of no more/equal to 3 mg/kg/day
•Negative cancer screening conducted in the 12 months prior to screening visit
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

•Dermatomyositis patients having overlap myositis or any other type of myositis including paraneoplastic myositis, drug-induced myopathy, necrotizing myositis
•Preexisting severe cardiac or pulmonary conditions, malignancy of any organ system or significant eye diseases.
•Uncontrolled diabetes mellitus or diabetes complicated with organ involvement.
•Pregnant or nursing (lactating) women
•Other protocol-defined inclusion/exclusion criteria apply.

发起方